GLP-1 Research Tracker

Get smarter about GLP-1s every morning.

The top 3 papers from NEJM, Lancet & Nature—decoded in plain English.

The research moving the GLP-1 market, before it hits the headlines.

0+
Papers analyzed
0
Top journals
Daily
Fresh insights

What readers are saying

This resource is invaluable. It is challenging keeping up to date within this fast moving field even for experts, so being able to get the key messages from a paper in a few minutes following a critical assessment and balanced presentation is very useful for busy healthcare professionals.
Prof Alex Miras
Prof Alex Miras
Professor and Consultant in Endocrinology
Institution logo
This website is invaluable. It cuts through the noise and ensures decisions whether clinical, regulatory, or strategic are grounded in the latest, most reliable insights.
Prof Sam Shah
Prof Sam Shah
UCL Global Business School for Health
Institution logo
As an academic, the summaries really help me sieve through and focus on impactful, forward thinking research.
Dr Meenakshi Jhala
Dr Meenakshi Jhala
NIHR Academic Clinical Fellow
Institution logo
This digest has become my secret weapon for staying ahead of the GLP-1 space. I scan it every morning before my team meetings.
Kiran Jones
Kiran Jones
Product and Content Lead, Oxford Online Pharmacy
My go-to source to see what's new that matters, and track research by topic. It's a 4D version of Google Alerts.
Jeremy Shane
Jeremy Shane
Venture Partner, NextGen Venture Partners
Institution logo
Simply brilliant.
Mia Silverio
Mia Silverio
Research Lead, Prof G Media
Institution logo
Turned a paper from Monday's digest into our best-performing content piece. This thing pays for itself.
Aamir Hussain
Aamir Hussain
CEO, Ace Creative Labs
I've recommended this to every doctor I know in the weight loss space. It's the edge we all need.
Dr Rashi Malhotra
Dr Rashi Malhotra
Family and Lifestyle Medicine Doctor
Institution logo
This resource is invaluable. It is challenging keeping up to date within this fast moving field even for experts, so being able to get the key messages from a paper in a few minutes following a critical assessment and balanced presentation is very useful for busy healthcare professionals.
Prof Alex Miras
Prof Alex Miras
Professor and Consultant in Endocrinology
Institution logo
This website is invaluable. It cuts through the noise and ensures decisions whether clinical, regulatory, or strategic are grounded in the latest, most reliable insights.
Prof Sam Shah
Prof Sam Shah
UCL Global Business School for Health
Institution logo
As an academic, the summaries really help me sieve through and focus on impactful, forward thinking research.
Dr Meenakshi Jhala
Dr Meenakshi Jhala
NIHR Academic Clinical Fellow
Institution logo
This digest has become my secret weapon for staying ahead of the GLP-1 space. I scan it every morning before my team meetings.
Kiran Jones
Kiran Jones
Product and Content Lead, Oxford Online Pharmacy
My go-to source to see what's new that matters, and track research by topic. It's a 4D version of Google Alerts.
Jeremy Shane
Jeremy Shane
Venture Partner, NextGen Venture Partners
Institution logo
Simply brilliant.
Mia Silverio
Mia Silverio
Research Lead, Prof G Media
Institution logo
Turned a paper from Monday's digest into our best-performing content piece. This thing pays for itself.
Aamir Hussain
Aamir Hussain
CEO, Ace Creative Labs
I've recommended this to every doctor I know in the weight loss space. It's the edge we all need.
Dr Rashi Malhotra
Dr Rashi Malhotra
Family and Lifestyle Medicine Doctor
Institution logo

See what lands in your inbox

Every weekday at 8AM EST.

Subject:What's the latest signal in GLP-1 research?

Good morning! Here are today's 3 must-read papers.

NEJMRCT4High evidence#1

Tirzepatide delivers 22.5% weight loss at 72 weeks in SURMOUNT-1

Why it matters: This is the largest weight loss ever seen in a clinical trial for obesity medication.

LancetRCT4High evidence#2

Semaglutide reduces major cardiovascular events by 20% in SELECT

Why it matters: First proof that weight loss drugs can prevent heart attacks and strokes.

NatureMeta5Highest evidence#3

Oral GLP-1 absorption enhanced 10x with new delivery system

Why it matters: Could make daily pills as effective as weekly injections.

Latest Research

Curated from the world's top medical journals, updated every day.

Filter by categoryFilter by journalSort by evidence strength
Updated daily from PubMed

Tap any paper for the full summary →

Filter by Journal

Evidence Strength

5highestto1lowest
50 papers
New4 days ago
Diabetes Obes Metab

Nationwide Real-World Retrospective Study of Oral Semaglutide Use in Adults Living With Type 2 Diabetes in Finland.

Summary pending...

Vaden A, Lahelma M, Nurmi L, Heikkilä E, Vessari H, Luoto H, Saukkonen T, Niskanen L

New5 days ago
Nat Med

Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial.

Summary pending...

Pratley RE, Denham DS, Trivedi R, Watkins E, Connery L, Barnes J, Yu D, Hong J, Simard C, Umans K, Liu L, Tirucherai GS, Marantz JL

New5 days ago
Diabetes Obes Metab

Optic Ischaemic Neuropathy in Incretin-Based Therapy: A Comparative Analysis of Real-World Safety Data.

Summary pending...

Kakkar AK, Payra S, Charaya A

New5 days ago
Diabetes Obes Metab

Investigating the Incremental Cost and Utilization Burden of Obstructive Sleep Apnea in Overweight to Severely Obese Patients.

Summary pending...

Kim HSJ, Tran TH, Schmickl CN, Slejko JF

New5 days ago
Diabetes Obes Metab

Perioperative Desaturation and Postoperative Nausea or Vomiting Requiring Antiemetic Administration in Glucagon-Like Peptide-1 Receptor Agonist Users Undergoing Ambulatory Ophthalmic Surgery Under Mild-To-Moderate Sedation: A Large Retrospective Cohort Study.

Summary pending...

Hyung B, Ye XY, Chandrakumar M, Lovshin JA, Peacock SC

New5 days ago
Diabetes Obes Metab

Risk of Age-Related Ocular Diseases in Non-Diabetic Adults With Obesity Using Glucagon-Like Peptide 1 Receptor Agonists.

Summary pending...

Chen KE, Wang PC, Lin HA, Lin SF

New5 days ago
Lancet

Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial.

Summary pending...

Aroda VR, Davies MJ, Maaske J, Millegård M, Juan VL, Aberle J, Ciudin A, McCrimmon RJ, Eklund O, Shih JL, Sjostrand M, Zarzuela D, Rosenstock J

New5 days ago
Lancet

Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.

Summary pending...

Welch M, Forst T, Jia W, Del Pino PO, Denning M, Wu WS, Li J, Liu R, Eifu M, Chen Y, ACHIEVE-2 Trial Investigators

New5 days ago
Lancet

Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial.

Summary pending...

Davies MJ, Aroda VR, Rosenstock J, Capehorn M, Pedersen SD, Morizzo E, Malhotra S, Johansson PA, Grice D, Andersson A, Rizi EP, Sjöström CD

New5 days ago
Ann Intern Med

Continuing Glucagon-Like Peptide-1 Receptor Agonists Into the First Trimester of Pregnancy and Pregnancy Outcomes : A Target Trial Emulation Study Using Claims Information.

Summary pending...

Brown JP, Huybrechts KF, Straub L, Patorno E, Seely EW, Bateman BT, Hernández-Díaz S

New5 days ago
JAMA Intern Med

Early Generic Semaglutide in Canada-Implications for US Patients and Policy.

Summary pending...

Tu SS, Kesselheim AS, Tadrous M, Beall RF

New5 days ago
N Engl J Med

Survodutide Once Weekly for the Treatment of Adults with Obesity.

Summary pending...

le Roux CW, Wharton S, Startseva E, Kloer IM, Hussain SA, Unseld A, Bozkurt B, Ard JD, Bays HE, Bogdański P, Ekinci EI, Jastreboff AM, Ji L, Ogawa W, Pedersen SD, Pietiläinen KH, Sattar N, Seufert J, Stenlöf K, van Beek AP, Vangoitsenhoven R, Brueckmann M, Younes R, Kaplan LM, SYNCHRONIZE-1 Investigators

New5 days ago
Diabetes Obes Metab

Glucocorticoid-Induced Hyperglycaemia in Hospital: The Insulin Dose Matters Most.

Summary pending...

Burt MG, Khalili F, Radhakutty A, Chen AX

New6 days ago
Nat Med

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.

Summary pending...

Kaplan LM, Startseva E, le Roux CW, Wharton S, Bozkurt B, Mazo DF, von Schlippenbach J, González Maldonado S, Ajaz Hussain S, Neff GW, Gonzalez Rojas Y, Smith C, Younes R, Sanyal AJ, SYNCHRONIZE-MASLD Investigators

New6 days ago
Obesity (Silver Spring)

Use of Glucagon-Like Peptide-1 Receptor Agonists in Danish Adolescents and Young Adults 2018-2025.

Summary pending...

Kildegaard H, Andersen JH, Vinding RK, Kloppenborg JT, Pottegård A

New6 days ago
Lancet Diabetes Endocrinol

Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.

Summary pending...

Aroda VR, Buzzetti R, Dalskov SM, Jain AB, Larsen JH, Mathieu C, Pratley RE, Videmark A, Watt T, Buse JB

New6 days ago
Lancet Diabetes Endocrinol

Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.

Summary pending...

Buse JB, Bajaj HS, Dalskov SM, Donaldson L, Hansen Duus HH, Fabricius TW, Haluzík M, Lingvay I, Pedersen SD, Pratley RE, Jain AB, REIMAGINE 2 study group

New6 days ago
Lancet

Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.

Summary pending...

Rosenstock J, Billings LK, Gajria R, Giorgino F, Johansen NB, Klein KR, Thamattoor UK, Buse JB, Jain AB

New6 days ago
JAMA

Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial.

Summary pending...

Giorgino F, D'Souza S, Ludwig L, Kiyosue A, Ibriga H, Rha H, Denning M, Wu WS, Fernández Landó L, Tobian J

New6 days ago
Diabetes Care

Evolocumab in Patients With High-Risk Diabetes: Results From the VESALIUS-CV Trial.

Summary pending...

Leiter LA, Giugliano RP, Marston NA, De Ferrari G, Nicolau JC, Bhatia AK, Cyrille M, Park JG, Kuder JF, Murphy SA, Liu L, Walsh E, Wang H, Džupina A, Ferreira J, Gouni-Berthold I, Jensen HK, Kuusisto J, Pella D, Sattar N, Tsioufis KP, Vinereanu D, Paiva da Silva Lima G, Sabatine MS, Bohula EA

New6 days ago
JAMA

Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.

Summary pending...

Gao L, Jiang H, Cai H, Tian J, Shi B, Qiu W, Huang C, Han J, Zhang S, Pang S, Bi Y, Chen L, Gu X, Han J, Ma Q, Deng H, Wang Y, Li L, Han-Zhang H, Qian L, Ji L, GLORY-2 Trial Investigators

New7 days ago
Lancet

Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.

Summary pending...

Bajaj HS, Welch M, Shah P, Luna E, Jaouimaa FZ, Liu B, Liu R, Chen Y, Patel H, Bartee A

Last week
Nat Med

Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial.

Summary pending...

Rosenstock J, Lingvay I, Ryan D, Jastreboff AM, Kushner R, Acosta A, Blevins TC, Choi M, Holmes FL, Smith T, Connery L, Li Y, Liu MK, Barth A, Butcher J, Civitarese A, Yue H, Coll B, ACCESS Trial Investigators

Last week
JAMA Netw Open

Patient Experiences With GLP-1 Receptor Agonists.

Summary pending...

de Vere Hunt I, Ramirez-Posada M, Babu CS, Brown-Johnson C, Linos E, Rodriguez F

Last week
Diabetes Obes Metab

Rates of, Reasons for, and Reactions to Discontinuation of GLP-1 Receptor Agonists: A Narrative Review.

Summary pending...

Heisey HD, Gregg LP, Verrico CD, Villareal DT, Fletcher TL

Last week
Diabetes Obes Metab

Glucagon-Like Peptide-1 Based Therapies and the Risk of Severe Gastrointestinal Motility Adverse Events: A Cohort Study.

Summary pending...

Alkabbani W, Crisafulli S, Paik JM, Tavakkoli A, Bykov K, Glynn RJ, Wexler DJ, Patorno E

Last week
Diabetes Obes Metab

Heterogeneity of Treatment Effects Across Nine Glucose-Lowering Drug Classes in Type 2 Diabetes: Extension of the LEGEND-T2DM Network Study.

Summary pending...

Chen HY, Falconer T, Ostropolets A, Anand TV, Jiang X, Dávila-García D, Zhang L, Fan R, Morgan-Cooper H, Suchard MA, Hripcsak G

Last week
Diabetes Obes Metab

Short-Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open-Label, Randomised Controlled Trial.

Summary pending...

Yang Z, Xu Y, Du H, Liu W, Chen H, Liu D, Zhang L, Wang C

Last week
JAMA Netw Open

HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized Clinical Trial.

Summary pending...

Guo L, Sun Z, Zhang L, Qin G, Li Y, Chen X, Xu N, Su X, Mao L, Sun J, Cheng Z, Shi X, Wang F, Wang Q, Pan R, Ding S, Ye Z, Xu Y, Liu P

Last week
Diabetes Obes Metab

Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial.

Summary pending...

Heise T, Zijlstra E, Mari A, Roell WC, Mather KJ, Haupt A, Flevaris P, Liao R, Chua L, Harris C, Pratt EJ

Last week
Int J Obes (Lond)

The impact of adjuvant anti-obesity medications on 10-year weight loss outcomes after sleeve gastrectomy.

Summary pending...

Hornick MA, Duffy AJ, Floch NR, Morton JM

Last week
Diabetes Obes Metab

Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison.

Summary pending...

Michalak W, Bøg M, Bendixen T, Chowdhury R, Cowley P, Laugesen C, Rathor N, Kushner RF

Last week
Diabetes Obes Metab

Acute GIP and GLP-1 Administration Exerts Differential Metabolic Effects in Totally Pancreatectomised Individuals.

Summary pending...

Krogh LSL, Hansen MB, Bergmann NC, Hansen CP, Hartmann B, Holst JJ, Knop FK, Lund AB, Gasbjerg LS

Last week
Diabetes Obes Metab

Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes.

Summary pending...

Plotkin M, Ivkovic M, Smith I, Rathor N, Chowdhury R, Hodkinson A, Kushner RF

Last week
Obesity (Silver Spring)

Musculoskeletal Outcomes of Glucagon-Like Peptide-1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults.

Summary pending...

Wu JS, Lin LY, Sun JW, Yu WT, Yuliani FS, Lin SH

Last week
Ann Intern Med

In T2D inadequately controlled with metformin, orforglipron reduced HbA(1c) more than oral semaglutide at 52 wk.

Summary pending...

Lau D, ACP Journal Club Editorial Team at McMaster University

Last week
J Med Internet Res

Affordable GLP-1? When Digital Platforms Meet Policy Reform.

Summary pending...

Zhan XJ

Last week
Diabetes Obes Metab

The Impact of GLP-1-Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta-Analysis.

Summary pending...

Chuang SM, Liu SC, Chien KL, Lin CJ, Tsai MC, Shih HM

Last week
Diabetes Obes Metab

Semaglutide Injection in Indian Patients With Type 2 Diabetes Mellitus: A Randomised, Phase III, Active-Controlled Study.

Summary pending...

Ambika Gopalakrishnan U, Joshi AS, Giri R, Shah SJ, Shukla J, Maheshwari S, M Chowdaiah R, Singh MK, Bari AS, Pathak NP, Shah AN, Bhandari S, Gowda A, Chandrappa A, Supe PD, Das B, Sharma PK, Virani MK, Kurmi PH, Ghanekar GA, Dasari MD, Sahoo B, Jangid SK, Shende PS, Patil SS, Kumbhar AN, Deshpande SV, Chennappa M, Patel NC, Sonawane D, Patil D, Pandit S, Ghadge P, Mehta S

Last week
Diabetes Obes Metab

Evaluation of the Safety, Efficacy and Pharmacokinetics of BGM0504 in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double-Blind Phase II Trial.

Summary pending...

Jin P, Ji L, Huang Y, Ding H, Xie D, Jiang X, Yuan X, Cao Z, Zhang H, Yuan J

Last week
Diabetes Obes Metab

Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial.

Summary pending...

Yokote K, Yamauchi T, Fukushima Y, Takatsuka Y, Kato M, Yan S, Inoue T, Borowska L, Brueckmann M, Ogawa W, SYNCHRONIZE‐JP Trial Investigators

2 weeks ago
Diabetes Obes Metab

Risk of Psychiatric Worsening With GLP-1 Receptor Agonist Use in Patients With Type 2 Diabetes and Treated Depression.

Summary pending...

Chang Y, Hsieh MH, Ju PC, Chang CC

2 weeks ago
Diabetes Obes Metab

GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology.

Summary pending...

De Fano M, Haurum LL, Schwarz CR, Porcellati F, Andersen A

2 weeks ago
Diabetes Obes Metab

Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials.

Summary pending...

Wachiraphansakul N, Vongchaiudomchoke T, Manosroi W, Ruengorn C, Noppakun K, Ngamvichchukorn T, Sood MM, Thavorn K, Hutton B, Nochaiwong S

2 weeks ago
Lancet Diabetes Endocrinol

Beyond weight loss: multisystem benefits of obesity medications.

Summary pending...

Savas M, Kuckuck S, Boon MR, van Rossum EFC

2 weeks ago
J Med Internet Res

After the Prescription: The Clinical Support Gap in Telehealth-Based GLP-1 Care.

Summary pending...

Zucker A

2 weeks ago
Diabetes Care

Renal Lipotoxicity: Mechanisms and Therapeutic Perspectives.

Summary pending...

Zaitoon H, Feigin E, Abdul-Ghani M, Clarke GD, Tuttle KR, DeFronzo RA

2 weeks ago
Diabetes Obes Metab

Real-World Effectiveness and 12-Month Persistence of a Semaglutide-Supported Digital Weight-Loss Service: A Retrospective Cohort Study in Germany.

Summary pending...

Talay L, Hom J, Tan M, Ahuja N

2 weeks ago
Diabetes Obes Metab

Impact of Time of Injection on the Efficacy and Safety of iGlarLixi Versus IDegAsp in Chinese People With Type 2 Diabetes: Exploratory Analysis of the Soli-D Study.

Summary pending...

Li X, Wang J, Liu T, Alvarez A, Lauand F, Melas-Melt L, Kang L, Du Q, Liu M

2 weeks ago
Diabetes Obes Metab

GLP-1 Receptor Agonists and Risk of Age-Related Macular Degeneration in Older Adults With Obesity: A Target Trial Emulation.

Summary pending...

Chang TW, Kuo CY, Lee CY, Hung CH

GLP-1 Research Tracker - Latest Obesity & Weight Loss Research